Cue Biopharma Announces Board and Officer Changes
Ticker: CUE · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1645460
Sentiment: neutral
Topics: management-change, officer-appointment, director-election
TL;DR
Cue Biopharma shakes up leadership and exec pay - new board members and officers appointed.
AI Summary
Cue Biopharma, Inc. announced on September 26, 2025, changes in its board and officer composition. The company filed an 8-K report detailing the departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for its key executives.
Why It Matters
Changes in a company's leadership and executive compensation can signal shifts in strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and officer composition can indicate internal shifts that may affect company strategy and performance.
Key Numbers
- 001-38327 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3324577 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- September 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 40 Guest Street Boston, Massachusetts 02135 (address) — Principal executive offices
- Imagen Biopharma, Inc. (company) — Former company name
FAQ
What specific roles have been affected by the officer appointments?
The filing indicates the appointment of certain officers but does not specify the exact roles in the provided text.
Were there any specific reasons cited for the departure of directors or officers?
The filing states 'Departure of Directors or Certain Officers' as an item of disclosure but does not provide specific reasons for any departures in the excerpt.
What are the details of the compensatory arrangements for the newly appointed officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as a disclosed item, but the specific details of these arrangements are not included in the provided text.
When was Cue Biopharma, Inc. formerly known as Imagen Biopharma, Inc.?
The company was formerly known as Imagen Biopharma, Inc. with a date of name change on June 17, 2015.
What is the primary business of Cue Biopharma, Inc. according to the filing?
Cue Biopharma, Inc. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 2,123 words · 8 min read · ~7 pages · Grade level 12.8 · Accepted 2025-09-29 16:00:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
- $620,000 — m will be paid an annual base salary of $620,000. Following the end of each calendar yea
- $838,750 — severance payment in an amount equal to $838,750, less all applicable taxes and withhold
Filing Documents
- cue-20250926.htm (8-K) — 85KB
- 0000950130-25-000140.txt ( ) — 215KB
- cue-20250926.xsd (EX-101.SCH) — 44KB
- cue-20250926_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Appointment and Resignation On September 26, 2025, the Board of Directors (the "Board") of Cue Biopharma, Inc. (the "Company") appointed Usman Azam as President and Chief Executive Officer and as a member of the Board, in each case effective as of September 29, 2025 (the "Effective Date"). Dr. Azam will succeed Daniel R. Passeri whose retirement and resignation as Chief Executive Officer and as a member of the Board will be effective as of the Effective Date. Following his resignation, Mr. Passeri will continue to serve as a strategic advisor in a consulting capacity to the Company. Employment Agreement with Dr. Azam Prior to joining the Company, Dr. Azam, age 57, served as chief executive officer of Inspirna, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs, from March 2023 until May 2025. From January 2022 until February 2023, Dr. Azam was chief executive officer of Empyrean Neuroscience, Inc., a genetic engineering company. From December 2016 to January 2022, he served as president and chief executive officer of Tmunity Therapeutics, Inc., a biotechnology company acquired by Kite Pharma, a Gilead company, in 2023. Prior to joining Tmunity, Dr. Azam served in various senior research and development leadership roles in the United States and Switzerland, including as global head of cell and gene therapies at Novartis from March 2009 to November 2016. Dr. Azam served as chief executive officer of NovAccel Therapeutics from April 2008 to March 2009. Dr. Azam was the chief medical officer of Aspreva Pharmaceuticals from January 2007 to April 2008. Dr. Azam previously held positions at Johnson & Johnson from 2004 to 2006, including as chief medical officer of Ethicon, a Johnson & Johnson company. Earlier in his career
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: September 29, 2025 By: /s/ Usman Azam Name: Usman Azam Title: President and Chief Executive Officer